A clinical study to evaluate confirmity to treatment, illness result, and quality-of-life in patients with advanced brain tumor (glioma) treated with uninterrupted short-course hypofractionated radiation therapy
- Conditions
- Health Condition 1: null- High grade Glioma
- Registration Number
- CTRI/2012/11/003141
- Lead Sponsor
- Tata Memorial Centre Tata Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 55
1.Poor-prognosis HGG defined as
a] Patient aged >18 but <=50 years with KPS <=40 and/or NPS>=3
b] Patients aged >50 but <=65 years with KPS <=60 and/or NPS >=2
c] Patients over >65 years of age with KPS <=80 and/or NPS >=1
2. Histo-pathologically proven HGG including variants 3. Available pre-surgical imaging (CT/MRI)
4. Written informed consent from patient/care- giver
5. Adjuvant therapy starting within 6 weeks (preferably within 4 weeks) of surgery
6. Life-expectancy of at least 3 months
1 Children 18 years of age
2 Patients deemed suitable for conventionally fractionated radiotherapy
3 Unconfirmed histology
4 Recurrent/progressive disease or
transformed HGG from previous low-grade glioma
5 Carmustine wafers implanted at surgery
6 Pregnancy or lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Compliance to continuous short-course hypofractionated radiation therapyTimepoint: Two weeks
- Secondary Outcome Measures
Name Time Method a] Median survival in months, 6-month overall survival, and 1-year overall survival <br/ ><br> b] Change in QOL scores serially longitudinally over time <br/ ><br>Timepoint: 6 months to 1 year